Roggenkamp v. Morgan Stanley Medical Plan

CourtCourt of Appeals for the Ninth Circuit
DecidedJune 5, 2026
Docket24-7864
StatusUnpublished

This text of Roggenkamp v. Morgan Stanley Medical Plan (Roggenkamp v. Morgan Stanley Medical Plan) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Roggenkamp v. Morgan Stanley Medical Plan, (9th Cir. 2026).

Opinion

NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS JUN 5 2026 MOLLY C. DWYER, CLERK U.S. COURT OF APPEALS FOR THE NINTH CIRCUIT

MARC ROGGENKAMP, No. 24-7864 D.C. No. Plaintiff - Appellant, 2:23-cv-05531-WLH-AGR v. MEMORANDUM* MORGAN STANLEY MEDICAL PLAN,

Defendant - Appellee.

Appeal from the United States District Court for the Central District of California Wesley L. Hsu, District Judge, Presiding

Submitted May 18, 2026** Pasadena, California

Before: LEE, BUMATAY, and SUNG, Circuit Judges.

Marc Roggenkamp sued Morgan Stanley Medical Plan (“MS Plan”) to

recover benefits under the Employee Retirement Income Security Act

(“ERISA”), 29 U.S.C. § 1132(a). Cigna, the administrator of his plan, denied

* This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3. ** The panel unanimously concludes this case is suitable for decision without oral argument. See Fed. R. App. P. 34(a)(2). Roggenkamp’s pre-authorization request for a two-level artificial disc replacement

surgery (“two-level ADR”). Roggenkamp appeals the district court’s judgment in

favor of MS Plan after a bench trial. We have jurisdiction under 28 U.S.C. § 1291.

“We review de novo a district court’s choice and application of the standard of

review to decisions by fiduciaries in ERISA cases. We review for clear error the

underlying findings of fact.” Abatie v. Alta Health & Life Ins. Co., 458 F.3d 955,

962 (9th Cir. 2006) (en banc) (citation omitted). We affirm in part, and reverse and

remand in part.

1. The district court correctly concluded that Cigna did not operate under a

conflict of interest. We review an administrator’s decision for abuse of discretion

when “the benefit plan gives the administrator or fiduciary discretionary authority

to determine eligibility for benefits.” Saffon v. Wells Fargo & Co. Long Term

Disability Plan, 522 F.3d 863, 866 (9th Cir. 2008) (quoting Firestone Tire &

Rubber Co. v. Bruch, 489 U.S. 101, 115 (1989)). If the administrator operates

under a conflict of interest, “that conflict must be weighed as a ‘facto[r] in

determining whether there is an abuse of discretion.’” Firestone Tire & Rubber

Co., 489 U.S. at 115 (citation omitted) (alteration in original). A conflict exists

when an administrator both determines eligibility and pays for benefits. Metro. Life

Ins. Co. v. Glenn, 554 U.S. 105, 108 (2008); Abatie, 458 F.3d at 965. The plaintiff

bears the burden “to produce evidence of a financial conflict sufficient to warrant a

2 24-7864 degree of skepticism.” Deer v. IBM Corp. LTD Plan, 835 F.3d 893, 902 (9th Cir.

2016).

The parties agree that the MS Plan grants decision-making discretion to

Cigna, so the abuse of discretion standard applies. But the parties dispute whether

there was a conflict that should have resulted in less deference to Cigna’s decision.

As the administrator of the plan, Cigna adjudicated Roggenkamp’s claims and

determined eligible expenses, while Morgan Stanley funded the plan. Roggenkamp

has provided no evidence of a financial conflict, as he cannot show that Cigna both

determines eligibility and pays for benefits.

Roggenkamp’s allegations that Cigna delayed during the administrative and

legal process, repeated the same conclusory language in its denial letters, and

interrupted Roggenkamp’s physician in a peer-to-peer phone call do not

demonstrate a financial conflict of interest. His contention that “common law

agency principles” suggest Cigna’s actions may be attributable to the MS Plan is

incorrect and unsupported by the cited authority. See Salyers v. Metro. Life Ins.

Co., 871 F.3d 934, 939–41 (9th Cir. 2017) (evaluating common law agency

principles in considering whether an insurer is deemed to have the same

knowledge as the employer, but noting, “[o]ur holding in this case does not mean

that a policy-holder employer is always an agent of the insurer in every aspect of

plan administration in which it participates”). We affirm the district court’s

3 24-7864 conclusion that there is no conflict.

2. The district court erred in affirming the denial of benefits. ERISA requires

that a notice of claim denial contain: “(1) ‘[t]he specific reason or reasons for the

denial’; (2) ‘[r]eference to the specific plan provisions on which the determination

is based’; (3) ‘[a] description of any additional material or information necessary

for the claimant to perfect the claim and an explanation of why such material or

information is necessary’; and (4) ‘[a] description of the plan’s review procedures

and the time limits applicable to such procedures, including a statement of the

claimant’s right to bring a civil action under section 502(a) of the Act following an

adverse benefit determination on review.’” Collier v. Lincoln Life Assurance Co.,

53 F.4th 1180, 1185 (9th Cir. 2022) (alterations in original) (quoting 29 C.F.R. §

2560.503-1(g)(1)(i)–(iv)). Plan administrators must provide specific reasons for the

denial to “enable[] the claimant to prepare adequately for any further

administrative review, as well as appeal to the federal courts.” Harlick v. Blue

Shield of Cal., 686 F.3d 699, 720 (9th Cir. 2012) (quoting Mitchell v. CB Richard

Ellis Long Term Disability Plan, 611 F.3d 1192, 1199 n.2 (9th Cir. 2010)). Further,

a district court errs when it “relie[s] on new rationales to affirm the denial of

benefits—rationales that [the insurer] did not assert during the administrative

process,” because doing so deprives the claimant of the “opportunity to respond”

and denies them the “statutory right to ‘full and fair review’ of the denial of her

4 24-7864 claim.” Collier, 53 F.4th at 1182 (9th Cir. 2022) (quoting 29 U.S.C. § 1133(2)).

Here, in each denial letter, Cigna consistently informed Roggenkamp that it

was denying benefits because there were “not enough studies” to show two-level

ADR “is effective or improves health outcomes,” and Cigna cited only its internal

guidance, Medical Coverage Policy No. 0104 (“MCP”), which is a non-plan

document that categorically excludes two-level ADR as “experimental.” Cigna

never relied on the Summary Plan Description (“SPD”), which is undisputedly the

governing plan document, and which supersedes the MCP in the event of a

conflict.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Firestone Tire & Rubber Co. v. Bruch
489 U.S. 101 (Supreme Court, 1989)
Metropolitan Life Insurance v. Glenn
554 U.S. 105 (Supreme Court, 2008)
Marjorie Booton v. Lockheed Medical Benefit Plan
110 F.3d 1461 (Ninth Circuit, 1997)
Abatie v. Alta Health & Life Ins. Co.
458 F.3d 955 (Ninth Circuit, 2006)
Jeanene Harlick v. Blue Shield of California
686 F.3d 699 (Ninth Circuit, 2012)
Mark Stephan v. Unum Life Insurance Company Of
697 F.3d 917 (Ninth Circuit, 2012)
Pacific Shores Hospital v. United Behavioral Health
764 F.3d 1030 (Ninth Circuit, 2014)
Daniel Demer v. IBM Corp Ltd Plan
835 F.3d 893 (Ninth Circuit, 2016)
Susan Salyers v. Metropolitan Life Ins. Co.
871 F.3d 934 (Ninth Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Roggenkamp v. Morgan Stanley Medical Plan, Counsel Stack Legal Research, https://law.counselstack.com/opinion/roggenkamp-v-morgan-stanley-medical-plan-ca9-2026.